Cargando…
Overall survival of adult acute myeloid leukemia based on cytogenetic and molecular abnormalities during 5 years in a single center study
OBJECTIVES: To determined the 5-year overall survival (OS) rates for adult patients with acute myeloid leukemia (AML) patients at King Abdulaziz Medical City, Jeddah, Saudi Arabia, based on cytogenetic and molecular abnormalities. METHODS: A retrospective cohort study reviewing adult AML patient fil...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Saudi Medical Journal
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6901761/ https://www.ncbi.nlm.nih.gov/pubmed/31707416 http://dx.doi.org/10.15537/smj.2019.11.24584 |
_version_ | 1783477555367510016 |
---|---|
author | Alsobhi, Enaam M. Farahat, Fayssal M. Daghistani, Mustafa F. Awad, Khadeeja A. Al-Zahrani, Omar S. Al-Saiari, Afaf S. Koshak, Fai K. |
author_facet | Alsobhi, Enaam M. Farahat, Fayssal M. Daghistani, Mustafa F. Awad, Khadeeja A. Al-Zahrani, Omar S. Al-Saiari, Afaf S. Koshak, Fai K. |
author_sort | Alsobhi, Enaam M. |
collection | PubMed |
description | OBJECTIVES: To determined the 5-year overall survival (OS) rates for adult patients with acute myeloid leukemia (AML) patients at King Abdulaziz Medical City, Jeddah, Saudi Arabia, based on cytogenetic and molecular abnormalities. METHODS: A retrospective cohort study reviewing adult AML patient files between 2011 and 2018. Sixty-three patients were excluded due to pediatric age and secondary AML. The remaining 87 adult patients with de novo AML were enrolled in this study. RESULTS: The most frequent cytogenetic abnormalities were t(15;17) (17.2%), followed by complex cytogenetic (13.8%) and t(8;21) (5.7%). The most frequent molecular abnormalities were promyelocytic leukemia/retinoic acid receptor alpha (PML-RARA) (16.1%) and Nucleophosmin 1 (NPM1) (11.5%). The highest OS rate was associated with t(15;17), PML-RARA, and NPM. However, complex cytogenetic was associated with the lowest OS rate; fms-like tyrosine kinase 3 (FLT3)-internal tandem duplication was independently correlated with low OS rate. CONCLUSION: The study describes cytogenetic and molecular abnormalities observed in adult AML patients and gives an overview of prognostic factors and determine the OS, with comparable results with recent published data by the WHO. |
format | Online Article Text |
id | pubmed-6901761 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Saudi Medical Journal |
record_format | MEDLINE/PubMed |
spelling | pubmed-69017612021-02-26 Overall survival of adult acute myeloid leukemia based on cytogenetic and molecular abnormalities during 5 years in a single center study Alsobhi, Enaam M. Farahat, Fayssal M. Daghistani, Mustafa F. Awad, Khadeeja A. Al-Zahrani, Omar S. Al-Saiari, Afaf S. Koshak, Fai K. Saudi Med J Brief Communication OBJECTIVES: To determined the 5-year overall survival (OS) rates for adult patients with acute myeloid leukemia (AML) patients at King Abdulaziz Medical City, Jeddah, Saudi Arabia, based on cytogenetic and molecular abnormalities. METHODS: A retrospective cohort study reviewing adult AML patient files between 2011 and 2018. Sixty-three patients were excluded due to pediatric age and secondary AML. The remaining 87 adult patients with de novo AML were enrolled in this study. RESULTS: The most frequent cytogenetic abnormalities were t(15;17) (17.2%), followed by complex cytogenetic (13.8%) and t(8;21) (5.7%). The most frequent molecular abnormalities were promyelocytic leukemia/retinoic acid receptor alpha (PML-RARA) (16.1%) and Nucleophosmin 1 (NPM1) (11.5%). The highest OS rate was associated with t(15;17), PML-RARA, and NPM. However, complex cytogenetic was associated with the lowest OS rate; fms-like tyrosine kinase 3 (FLT3)-internal tandem duplication was independently correlated with low OS rate. CONCLUSION: The study describes cytogenetic and molecular abnormalities observed in adult AML patients and gives an overview of prognostic factors and determine the OS, with comparable results with recent published data by the WHO. Saudi Medical Journal 2019-11 /pmc/articles/PMC6901761/ /pubmed/31707416 http://dx.doi.org/10.15537/smj.2019.11.24584 Text en Copyright: © Saudi Medical Journal http://creativecommons.org/licenses/by-nc This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial License (CC BY-NC), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Brief Communication Alsobhi, Enaam M. Farahat, Fayssal M. Daghistani, Mustafa F. Awad, Khadeeja A. Al-Zahrani, Omar S. Al-Saiari, Afaf S. Koshak, Fai K. Overall survival of adult acute myeloid leukemia based on cytogenetic and molecular abnormalities during 5 years in a single center study |
title | Overall survival of adult acute myeloid leukemia based on cytogenetic and molecular abnormalities during 5 years in a single center study |
title_full | Overall survival of adult acute myeloid leukemia based on cytogenetic and molecular abnormalities during 5 years in a single center study |
title_fullStr | Overall survival of adult acute myeloid leukemia based on cytogenetic and molecular abnormalities during 5 years in a single center study |
title_full_unstemmed | Overall survival of adult acute myeloid leukemia based on cytogenetic and molecular abnormalities during 5 years in a single center study |
title_short | Overall survival of adult acute myeloid leukemia based on cytogenetic and molecular abnormalities during 5 years in a single center study |
title_sort | overall survival of adult acute myeloid leukemia based on cytogenetic and molecular abnormalities during 5 years in a single center study |
topic | Brief Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6901761/ https://www.ncbi.nlm.nih.gov/pubmed/31707416 http://dx.doi.org/10.15537/smj.2019.11.24584 |
work_keys_str_mv | AT alsobhienaamm overallsurvivalofadultacutemyeloidleukemiabasedoncytogeneticandmolecularabnormalitiesduring5yearsinasinglecenterstudy AT farahatfayssalm overallsurvivalofadultacutemyeloidleukemiabasedoncytogeneticandmolecularabnormalitiesduring5yearsinasinglecenterstudy AT daghistanimustafaf overallsurvivalofadultacutemyeloidleukemiabasedoncytogeneticandmolecularabnormalitiesduring5yearsinasinglecenterstudy AT awadkhadeejaa overallsurvivalofadultacutemyeloidleukemiabasedoncytogeneticandmolecularabnormalitiesduring5yearsinasinglecenterstudy AT alzahraniomars overallsurvivalofadultacutemyeloidleukemiabasedoncytogeneticandmolecularabnormalitiesduring5yearsinasinglecenterstudy AT alsaiariafafs overallsurvivalofadultacutemyeloidleukemiabasedoncytogeneticandmolecularabnormalitiesduring5yearsinasinglecenterstudy AT koshakfaik overallsurvivalofadultacutemyeloidleukemiabasedoncytogeneticandmolecularabnormalitiesduring5yearsinasinglecenterstudy |